Sarilumab 200 mg/1.14 ml subcutaneous solution [kevzara]_#1    (DrugBank: Sarilumab)

1 disease
IDDisease name (Link within this page)Number of trials
84Sarcoidosis1

84. Sarcoidosis    [ 143 clinical trials,   221 drugs,   (DrugBank: 79 drugs),   82 drug target genes,   165 drug target pathways]
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 143 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04008069
(ClinicalTrials.gov)
September 3, 201925/6/2019Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisA Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisSarcoidosisDrug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1;Drug: PlacebosStanford UniversityNULLRecruiting18 Years80 YearsAll15Phase 2United States